Valuation: Polaryx Therapeutics, Inc.

Market Cap 99.19M 85M 79.65M 72.75M 137M 9.46B 139M 939M 366M 4.77B 372M 364M 15.8B P/E 2026 *
-10.2x
P/E 2027 * -6.92x
Enterprise Value 99.19M 85M 79.65M 72.75M 137M 9.46B 139M 939M 366M 4.77B 372M 364M 15.8B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
30.08%
Yield 2026 *
-
Yield 2027 * -
1 day+6.42%
1 week-4.78%
Current month-13.85%
1 month-2.93%
3 months-44.72%
6 months-28.16%
1 week 1.85
Extreme 1.85
2.2
1 month 1.85
Extreme 1.85
2.68
Current year 1.85
Extreme 1.85
48.91
1 year 1.85
Extreme 1.85
48.91
3 years 1.85
Extreme 1.85
48.91
5 years 1.85
Extreme 1.85
48.91
10 years 1.85
Extreme 1.85
48.91
Manager TitleAgeSince
Chief Executive Officer 56 2023-02-28
Director of Finance/CFO 60 2024-05-31
Chief Tech/Sci/R&D Officer 59 2024-01-31
Director TitleAgeSince
Chairman 56 2021-05-31
Director/Board Member 60 2025-07-31
Director/Board Member - 2026-01-28
Date Insider Type Main position Quantity % Market Cap.
2/18/26 Buy

Chief Financial Officer

2,867 -
1/29/26 Other

Chief Technology Officer

150,358 -
1/29/26 Other

Chief Financial Officer

225,358 -
Change 5-day change 1-year change 3-year change Capi.($)
+6.42%-4.78% - - 99.19M
+1.02%+4.95%+3.67%+25.46% 51.65B
-0.09%-2.14%+492.60%+537.84% 45.31B
-0.32%+8.08%+37.97%+18.45% 42.7B
+1.18%+1.96%+21.95%+89.69% 42.79B
-2.27%-3.02%+14.22%+51.50% 32.87B
-0.96%+4.03%+31.55%+136.34% 17.14B
+0.41%+1.66% - - 16.61B
+1.12%+6.35%+11.00%+32.62% 15.01B
-0.31%+6.61%+81.37%+48.53% 14.21B
Average +0.60%+2.20%+86.79%+117.55% 27.84B
Weighted average by Cap. +0.03%+2.74%+104.70%+135.73%

Financials

2026 *2027 *
Net sales - -
Net income -9.16M -7.85M -7.36M -6.72M -12.68M -874M -12.81M -86.79M -33.79M -441M -34.41M -33.66M -1.46B -16.42M -14.07M -13.19M -12.05M -22.73M -1.57B -22.96M -156M -60.56M -790M -61.67M -60.33M -2.62B
Net Debt - -
Logo Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Its drug candidate pipeline includes PLX-200 (gemfibrozil), PLX-300 (cinnamic acid), PLX-100, and PLX-400. PLX-200 (gemfibrozil), its advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that the Company is pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. PLX-100 is a preclinical stage orally administrable combination therapy comprised of its PPARa agonist, PLX-200, and vitamin A, a RXRa agonist.
Employees
-
Date Price Change Volume
26-08-25 US$1.990 +6.42% 107,209
26-08-24 US$1.870 -9.66% 286,161
26-08-21 US$2.070 -3.27% 108,472
26-08-20 US$2.140 -0.93% 55,811
26-08-19 US$2.160 +3.35% 120,190
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.990USD
Average target price
7.500USD
Spread / Average Target
+276.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PLYX Stock